To investigate whether CLL cells respond to ferroptosis-inducing agents, eight different CLL cell lines (i.e., HG3, CII, PCL-12, Wa-C3CD5+, Mec-1, PGA-1, I83-E95, and JVM-3) were treated with GPX4 inhibitors (i.e., ML162 and RSL3) and an inhibitor of the xCt cystine transporter (i.e., erastin). Here, GPX4 is linked to B-cell chronic lymphocytic leukemia.